¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѳ»ºÐºñÇÐȸ (¿Â¶óÀÎ) AOCE-SICEM 2020 Virtual Congress : 2020-10-29

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇѳ»ºÐºñÇÐȸ (¿Â¶óÀÎ) AOCE-SICEM 2020 Virtual Congress : 2020-10-29
±³À°ÀÏÀÚ : 2020-10-29
±³À°Àå¼Ò : ¿Â¶óÀÎ ¿¬¼ö±³À°(½Ç½Ã°£ È­»ó °­ÀÇ), ¿Â¶óÀÎ ¿¬¼ö±³À°(³ìÈ­ °­¿¬ ¿µ»ó ¼ÛÃâ)  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) AOCE-SICEM 2020 Virtual Congress      
ÁÖÃÖ±â°ü : ´ëÇѳ»ºÐºñÇÐȸ
´ã´çÀÚ : ÇмúÀ§¿øȸ
¿¬¶ôó : 02-564-4367  
À̸ÞÀÏ : aoce-sicem2020@intercom.co.kr      
±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ÇÙÀÇÇаúÀÇ»çÇÐ, ºÐÀÚ»ý¹°ÇÐ,      
Âü¼®¿¹»óÀοø : 1500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 26 ½Ã°£ 20ºÐ  
¼¼ºÎ¼ö°­·á : 150,000¿ø      
ºñ°í 1. ÀÇ»ç, ±³¼ö - KES ȸ¿ø: 10¸¸¿ø / KES ¹Ìȸ¿ø: 15¸¸¿ø 2. Àü°øÀÇ, ÀüÀÓÀÇ, °£È£»ç, ¿¬±¸ÀÚ, ±âŸ - KES ȸ¿ø: 5¸¸¿ø / KES ¹Ìȸ¿ø: 10¸¸¿ø * º» Çà»ç´Â LIVE°­ÀÇ¿Í ³ìÈ­µÈ VOD°­ÀÇ·Î ÁøÇàµÇ¸ç, VOD °­ÀǵéÀº ¾Æ·¡ ½Ã°£¿¡ °ü°è¾øÀÌ ´çÀÏ ÀÚÁ¤±îÁö ÆíÇѽ𣿡 º¼ ¼ö ÀÖµµ·Ï ¿î¿µÇÒ ¿¹Á¤ÀÔ´Ï´Ù.      
       
±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 10¿ù 29ÀÏ ¿Â¶óÀΠ08:30~08:50 Hot Issues  () 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ08:50~09:30 Adrenal Masses – When to be Concerned: Benignity, Malignancy & More  Gary Hammer(University of Michigan) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ09:30~09:50 National Survey of Iodine Intake and Its Relations to Thyroid Disorders in Japan -Epidemiological Study on 32,000 Schoolchildren and 2500 Adults 2014 to 2019  Yozen Fuse(Foundation for Growth Science) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ09:50~10:10 Iodine Intake and Prevalence of Thyroid Disorders in Malaysia  Mafauzy Mohamed(Universiti Sains Malaysia) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ10:10~10:30 Autoimmunity, Iodine Status, Anemia, Stunting and Food Containing Iodine in IDD Replete Areas in Indonesia  Tjokorda Gde Dalem Pemayun(Diponegoro University) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ10:30~10:50 Elimination of Iodine Deficiency in Thailand: The Work Never Ends  Rajata Rajatanavin(Ramathibodi Hospital Mahidol University) 
Åä·Ð 10¿ù 29ÀÏ ¿Â¶óÀΠ10:50~11:00 Live Q&A  () 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ11:00~11:30 The Ominous Triad of Adipose Tissue Dysfunction: Inflammation, Fibrosis, and Impaired Angiogenesis  Clair Crewe(UT Southwestern Medical Center) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ11:30~12:00 Feeding-regulatory Peptides in Type 2 DM and Obesity  Masamitsu Nakazato(University of Miyazaki) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ12:00~12:30 Adipocyte Differentiation and Predisposition for T2DM among Asian Indians  Sri Venkata Madhu(UCMS-GTBHospital) 
È޽Ġ10¿ù 29ÀÏ ¿Â¶óÀΠ12:30~13:30 È޽Ġ () 
±âŸ 10¿ù 29ÀÏ ¿Â¶óÀΠ13:30~13:50 Opening Address  () 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ13:50~14:30 Role of Autophagy in the Development and Treatment of Diabetes  À̸í½Ä(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ14:30~15:00 Epidemiology of Postoperative Hypoparathyroidism in South Korea  ¾È¼ºº¹(ÀÌÈ­¿©´ë) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ15:00~15:30 Application of Big Data for Musculoskeletal Cell Differentiation Using DNase-seq  Yuuki Imai(Ehime University) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ15:30~16:00 Contributions to Osteoporosis and Metabolic Diseases Research in Asia: The Vietnam Osteoporosis Study (VOS)  Tuan Nguyen(Garvan Institute of Medical Research (Australia); Ton Duc Thang University (Vietnam)) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ16:00~16:30 Diagnostic Utility of Data Failed Cannulation of the Right Adrenal Vein in Primary Aldosteronism  ±èÀçÇö(¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø ³»ºÐºñ³»°ú) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ16:30~17:00 Metanephrine: Plasma vs Urine?  Roderick Clifton-Bligh(University of Sydney) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ17:00~17:30 Changing Concepts in Adrenal Insufficiency  Paul Stewart(University of Leeds) 
±âŸ 10¿ù 29ÀÏ ¿Â¶óÀΠ17:30~17:50 Daily Highlights  () 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ09:00~09:20 Screening, Diagnosis and Prognosis of Primary Aldosteronism  Vin-Cent Wu(National Taiwan University Hospital) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ09:20~09:40 Subtyping (Including AVS, Nuclear Medicine, and Other Methods) and Management  Takuyuki Katabami(St. Marianna University School of Medicine Yokohama City Seibu Hospital) 
Åä·Ð 10¿ù 29ÀÏ ¿Â¶óÀΠ09:40~11:10 Discussion  () 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ09:00~09:30 To Be Discussed  Kevin Williams(UT-Southwestern Medical Center/Internal Medicine) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ09:30~10:00 To Be Discussed  Young-Bum Kim(Harvard Medical School) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ10:00~10:30 Hypothalamic Control in Metabolic Function of Aging  ±è¹Î¼ö(Çѱ¹°úÇбâ¼ú¿¬±¸¿ø/°úÇбâ¼ú¿¬ÇÕ´ëÇб³) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ09:00~09:30 To Be Discussed  Hidetaka Suga(Nagoya University) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ09:30~10:00 Triacylglycerols: Biomarker to Biology  ±¸Ã¶·æ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ11:00~11:30 Cancer and Bone Interactions: Osteoblasts-Mediated Regulation of Anti-Tumoral Immunity in Bone  ¹Ú¼®ÀÎ(°í·Á´ëÇб³ ÀÇ°ú´ëÇÐ) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ11:30~12:00 Targeting RANKL in Bone Metastasis  Kazuo Okamoto(Graduate School of Medicine and Faculty of Medicine The University of Tokyo) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ12:00~12:30 (Pseudo) Hypoparathyroidism in Japan  Rieko Takatani(Chiba University) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ11:00~11:30 NAFLD and Cardiometabolic Diseases the Insight of Genetics  ±¸º¸°æ(¼­¿ïƯº°½Ã º¸¶ó¸Åº´¿ø) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ11:30~12:00 NAFLD and Cardiovascular Disease  Stergios Polyzos(Medical School Aristotle University of Thessaloniki) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ12:00~12:30 Management of NAFLD  Alice Pik Shan Kong(The Chinese University of Hong Kong) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ11:00~11:30 Sarcopenia and Sarcopenic Obesity in Cardiovascular Risk  ±èųâ(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ11:30~12:00 Blood Pressure Variation in Cardiovascular Risk  ±è¹Ì°æ(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ12:00~12:30 NAFLD and Subclinical Diastolic Heart Failure  °­Àº¼®(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ13:00~13:30 Overview of Familinal Hypercholesterolemia  ÀÌ»óÇÐ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ13:30~14:00 FH Management in Taiwan  Ta-Chen Su(National Taiwan University Hospital) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ14:00~14:30 Role of PCSK9 inhibitor in patients with FH  Brian Tomlinson(Macau University of Science & Technology) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ15:00~15:30 Making a Pituitary Gland in a Dish  Hidetaka Suga(Nagoya University) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ15:30~16:00 Precision Medicine in Pituitary Diseases  ±¸Ã¶·æ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ15:00~15:30 CARERARE-Platform for Rare Diseases Using Nation-wide Big Data  ¹èÀçÇö(°í·Á´ëÇб³ ¾È¾Ïº´¿ø) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ15:30~16:00 The Rare Diseases and Pediatric Clinical Research Networks in Europe  Jacques Demotes(ECRIN) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ16:00~16:30 Rare Endocrine Disease-common Data Model (RED-CDM)  È«³²±â(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ16:30~17:00 Thyroid Function & Quality of Life of Patients  Shuhang Xu(Nanjing University of Chinese Medicine) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ17:00~17:30 Thyroid Function and Metabolic Parameters of Patients  ±è¹ÎÈñ(ÀºÆò¼º¸ðº´¿ø) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ17:30~18:00 T3/T4 Combination Therapy in Hypothyroidism  ±è¿ø¹è(¼­¿ï¾Æ»êº´¿ø) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ16:30~17:00 Medical Treatment for Pediatric Thyroid Cancer  ÀÌ¿µ¾Æ(¼­¿ï´ëÇб³º´¿ø) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ17:00~17:30 Maximize Effectiveness of Radioiodine Treatment for Pediatric Differentiated Thyroid Cancer Patients  ¾Èº´Ã¶(°æºÏ´ëÇб³ ÀÇ°ú´ëÇÐ) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ17:30~18:00 Surgical Treatment for Pediatric Thyroid Cancer  Ken Kazahaya(Children¡¯s Hospital of Philadelphia) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ16:30~17:00 Diabetes & Metabolism Journal (DMJ)  Á¤Àΰæ(°æÈñÀÇ´ë °­µ¿°æÈñ´ëº´¿ø) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ17:00~17:30 About development strategy of JCEM  Paul Stewart(University of Leeds) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ17:30~18:00 Recent Progress of EnM and Future Strategy  ÀÌ¿ø¿µ(°­ºÏ»ï¼ºº´¿ø) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ16:30~16:50 Optimal Treatment in Patients with DM During COVID-19 Pandemic  ¹®Áؼº(¿µ³²ÀÇ´ë) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ16:50~17:10 Management of Adrenal Insufficiency Under SARS-CoV-2 Infection  Irina Bancos(Mayo Clinic) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ17:10~17:30 How to Manage Thromboembolic Risk Under SARS-CoV-2 Infection  Beverley J Hunt(Thrombosis & Haemophilia Centre) 
±³À°½Ã°£ 10¿ù 29ÀÏ ¿Â¶óÀΠ17:30~17:50 Role of Vitamin D Supplement During COVID-19  ¹èÀçÇö(°í·Á´ëÇб³¾È¾Ïº´¿ø) 
±âŸ 10¿ù 29ÀÏ ¿Â¶óÀΠ17:50~18:00 Q&A  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѳ»ºÐºñÇÐȸ (¿Â¶óÀÎ) AOCE-SICEM 2020 Virtual Congress : 2020-10-29""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ÀºÆò±¸ÀÇ»çȸ Á¦5Â÷¿¬¼ö±³À° : 2020-10-29
´ÙÀ½±Û (¿Â¶óÀÎ) ÀÇ·á±â°ü Á¾»çÀÚ ´ë»ó ¿¬¸íÀÇ·á°áÁ¤Á¦µµ ½ÉÈ­(ÀÇ·áÀÎ)±³À° : 2020-10-28
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20649 ´ëÀü °ø°ø±â°ü ÀçÁ÷ÀÇ»ç Ãá°è Çмú´ëȸ (1ÀÏÂ÷) : 2024-05-23 0 7 2024-05-10
20648 ¼­¿ï ÀºÆò±¸ÀÇ»çȸ Á¦1Â÷¿¬¼ö±³À°(ºóÇ÷ ¹× ÃâÇ÷ Áúȯ, ÀÏÂ÷ ÀÇ·á±â°ü¿¡¼­ÀÇ °ü¸®) : 2024-05-23 0 12 2024-05-10
20647 ´ëÀü ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ ´ëÀüÃæûÁöȸ - Á¦2Â÷ ¿ù·ÊÁý´ãȸ : 2024-05-23 0 15 2024-05-10
20646 Á¦ÁÖ ´ëÇÑÇǺΰúÇÐȸ Á¦ÁÖÁöºÎȸ 2024³â Á¦1Â÷ Áý´ãȸ : 2024-05-22 0 9 2024-05-10
20645 ´ë±¸ ´ëÇѾȰúÇÐȸ ´ë±¸°æºÏÁöȸ ¿¬¼ö±³À°-¹é³»Àå ¹× Àü¾ÈºÎ ÃֽŠÁö°ß : 2024-05-21 0 8 2024-05-10
20644 ¼­¿ï ¾çõ±¸ÀÇ»çȸ Ãá°è¿¬¼ö±³À°(Á¦2Çü ´ç´¢º´°ú ¸¸¼º ½ÅÀ庴, ÀÎÁöÀå¾Ö, ¸ÞŸ¹ö½º¿Í ÀÇ·á Çõ¸í) : 2024-05-21 0 12 2024-05-10
20643 ÃæºÏ 2024 Á¦Ãµ½ÃÀÇ»çȸ Ãá°è ¿¬¼ö°­Á : 2024-05-21 0 5 2024-05-10
20642 ºÎ»ê Á¦28Â÷ ¾Æ½Ã¾Æ-¿À¼¼¾Æ´Ï¾Æ »êºÎÀΰú¿¬¸Í Çмú´ëȸ (AOFOG 2024) (4ÀÏÂ÷) : 2024-05-20 0 12 2024-05-10
20641 ¼­¿ï ´ëÇÑÀÓ»ó³ëÀÎÀÇÇÐȸ 2024 Ãá°è ³ëÀÎÀÇÇÐ ¿¬¼ö°­Á : 2024-05-19 0 22 2024-05-10
20640 ¼­¿ï ´ëÇÑÀçÈ°ÀÇÇаúÀÇ»çȸ Stanley Lam ¿öÅ©¼¥ : 2024-05-19 0 32 2024-05-10
20639 ¼­¿ï Á¦40ȸ ´ëÇѳëÀÎÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-19 0 20 2024-05-10
20638 ¼­¿ï ´ëÇÑÁ¾¾ç¿Ü°úÇÐȸ 2024³âµµ ¿¬¼ö°­Á : 2024-05-18 0 14 2024-05-10
20637 ÀÎõ 2024³âµµ Á¦47Â÷ ´ëÇѺ¹ºÎ¿µ»óÀÇÇÐȸ Çмú´ëȸ(2ÀÏÂ÷) : 2024-05-18 0 7 2024-05-10
20636 Àü³² 2024 Á¦2Â÷ ´ëÇѾȰúÀÇ»çȸ ½ÉÆ÷Áö¿ò : 2024-05-18 0 1 2024-05-10
20635 ¼­¿ï ´ëÇÑÇǺκ´¸®ÇÐȸ Á¦22ȸ ÇǺκ´¸® ½ÉÆ÷Áö¿ò : 2024-05-18 0 32 2024-05-10
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷